Application of a standardized cytomegalovirus antigenemia assay in the management of patients with AIDS.
One-hundred twenty AIDS patients, tested by an optimized cytomegalovirus antigenemia (CMV-Ag) assay, were followed over a 6-month period in an attempt to correlate viral (CMV) load with severe CMV organ-specific disease. Among patients available for follow-up, CMV organ-specific disease was present in seven of eight (88%) with pp65 antigen levels > or = 50 cells per 4 x 10(5) polymorphonuclear leukocytes. One-hundred six patients of 107 patients with levels < 50 pp65 reactive cells did not develop CMV organ-specific disease within our 6-month follow-up period. The CMV-Ag assay, as standardized in our clinical setting, served as a marker and predictor of CMV organ-specific disease in our AIDS patient population.